Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 29 - The Oversight of Clinical Innovation in a Medical Marketplace

  • from Section IIB - Widening the Lens
  • Edited by Graeme Laurie, University of Edinburgh, Edward Dove, University of Edinburgh, Agomoni Ganguli-Mitra, University of Edinburgh, Catriona McMillan, University of Edinburgh, Emily Postan, University of Edinburgh, Nayha Sethi, University of Edinburgh, Annie Sorbie, University of Edinburgh
  • Book:
    The Cambridge Handbook of Health Research Regulation
    Published online:
    09 June 2021
    Print publication:
    24 June 2021, pp 287-295
    • Chapter
      • You have access
      • Open access
    • PDF
    • HTML
    • Export citation

  • Summary

    Clinical innovation is ubiquitous in medical practice and is generally viewed as both necessary and desirable. While innovation has been the source of considerable benefit, many clinical innovations have failed to demonstrate evidence of clinical benefit and/or caused harm. Given uncertainly regarding the consequences of innovation, it is broadly accepted that it needs some form of oversight. But there is also pushback against what is perceived to be obstruction of access to innovative interventions. In this chapter, we argue that this pushback is misguided and dangerous – particularly because of the myriad competing and conflicting interests that drive and shape clinical innovation.